OptimizeRx Launches TelaRep™ to Support Physicians Treating Patients with Complex Diseases in COVID-19 World
2020年4月2日 - 9:31PM
OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital
health solutions for life science companies and payers, has
launched TelaRep™, its latest EHR-enabled digital health tool
designed to support physicians who are treating patients with
specialty drug therapies.
Before COVID-19 and social distancing,
physicians treating patients with complex diseases could consult
with medical science liaisons (MSLs) in their offices to ensure the
appropriate treatment plan. Now that COVID-19 severely restricts
these face-to-face interactions, there is a critical communication
gap that can put patients at risk.
TelaRep fills this gap by enabling the providers
to connect with the MSLs via on-demand video consults from within
their existing EHR workflow.
“The COVID-19 pandemic has hit our national
healthcare system just as there has been an increasing use of
complex, expensive specialty drugs,” said Steve Silvestro, chief
commercial officer of OptimizeRx. “In order to design the best
therapeutic treatment regimen for their patients, healthcare
providers need detailed information about these powerful specialty
medications. Combined with other existing restrictions on visits by
life science representatives, social distancing makes in-person
consults nearly impossible. We created TelaRep™ to fill this
communication gap.”
TelaRep is available to all life science
companies that subscribe to the OptimizeRx integrated
communications platform. Through this platform, life science
companies can digitally communicate with over half of the
healthcare providers in the U.S. – even when providers are working
remotely. Using advanced analytics, the platform ensures that
providers in need of MSL consults are connected to the appropriate
life science representative.
Silvestro continued: “As a mission-driven
digital health technology business, our goal is to empower
providers with solutions to help their patients and ensure that
advances in patient outcomes are not adversely affected by the
current crisis or any future restrictions of in-person gatherings.
Our team has done an amazing job enabling providers to get the
information they need to help their patients during this
unprecedented time.”
William Febbo, CEO of OptimizeRx, commented:
“With over 80,000 highly-trained MSL professionals sidelined at a
time when the sharing of clinical knowledge is key to specialty
medications, on-demand virtual consults via TelaRep could not have
come at a better time. Our suite of digital health technology
solutions allows us to reach a broad network of medical
professionals in a seamless, non-disruptive way. Given the growing
emphasis on telehealth and its increasing adoption rates, TelaRep
is ideally positioned to help all stakeholders as the market adopts
secure, video-centric methods for maintaining care and service
continuity.”
About OptimizeRxOptimizeRx®
(NASDAQ: OPRX), a digital health company, connects pharmaceutical
companies to patients and providers, offering greater
affordability, adherence and brand awareness at the point-of-care.
As the nation’s largest digital platform connecting life sciences
to the point-of-care, OptimizeRx provides a direct channel for
pharma companies, payers, medtech, and medical associations to
communicate with healthcare providers right within their workflow
and also directly to patients.
The cloud-based solution supports patient
adherence to medications and better healthcare outcomes with
real-time access to financial assistance, prior authorization,
education and critical clinical information. OptimizeRx provides
more than half of the ambulatory patient market with access to
these benefits through leading EHR platforms like Allscripts,
Amazing Charts and Quest, and directly via its mobile
communications platform and digital therapeutics SaaS platform.
For more information, follow the company on
Twitter, LinkedIn or visit www.OptimizeRx.com.
Important Cautions Regarding Forward
Looking StatementsThis press release contains
forward-looking statements within the definition of Section 27A of
the Securities Act of 1933, as amended, and such as in section 21E
of the Securities Act of 1934, as amended. These forward-looking
statements should not be used to make an investment decision. The
words 'estimate,' 'possible' and 'seeking' and similar expressions
identify forward-looking statements, which speak only as to the
date the statement was made. The company undertakes no obligation
to publicly update or revise any forward-looking statements,
whether because of new information, future events, or otherwise.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted, or quantified.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect
of government regulation, competition, and other material
risks.
OptimizeRx Contact Doug Baker,
CFOTel (248) 651-6568 x807 dbaker@optimizerx.com
Media Relations Contact Maira
Alejandra, Media Relations ManagerTel (754) 245-7070
malejandra@optimizerx.com
Investor Relations Contact Ron
Both, CMATel (949) 432-7557 oprx@cma.team
OptimizeRx (NASDAQ:OPRX)
過去 株価チャート
から 6 2024 まで 7 2024
OptimizeRx (NASDAQ:OPRX)
過去 株価チャート
から 7 2023 まで 7 2024